392 related articles for article (PubMed ID: 30987102)
1. PEG-OligoRNA Hybridization of mRNA for Developing Sterically Stable Lipid Nanoparticles toward In Vivo Administration.
Kurimoto S; Yoshinaga N; Igarashi K; Matsumoto Y; Cabral H; Uchida S
Molecules; 2019 Apr; 24(7):. PubMed ID: 30987102
[TBL] [Abstract][Full Text] [Related]
2. Optimization of DOTAP/chol Cationic Lipid Nanoparticles for mRNA, pDNA, and Oligonucleotide Delivery.
Sun M; Dang UJ; Yuan Y; Psaras AM; Osipitan O; Brooks TA; Lu F; Di Pasqua AJ
AAPS PharmSciTech; 2022 May; 23(5):135. PubMed ID: 35534697
[TBL] [Abstract][Full Text] [Related]
3. Induced packaging of mRNA into polyplex micelles by regulated hybridization with a small number of cholesteryl RNA oligonucleotides directed enhanced in vivo transfection.
Yoshinaga N; Uchida S; Naito M; Osada K; Cabral H; Kataoka K
Biomaterials; 2019 Mar; 197():255-267. PubMed ID: 30669016
[TBL] [Abstract][Full Text] [Related]
4. Lipid nanoparticles containing labile PEG-lipids transfect primary human skin cells more efficiently in the presence of apoE.
Gregersen CH; Mearraoui R; Søgaard PP; Clergeaud G; Petersson K; Urquhart AJ; Simonsen JB
Eur J Pharm Biopharm; 2024 Apr; 197():114219. PubMed ID: 38368913
[TBL] [Abstract][Full Text] [Related]
5. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
6. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production.
Suzuki T; Suzuki Y; Hihara T; Kubara K; Kondo K; Hyodo K; Yamazaki K; Ishida T; Ishihara H
Int J Pharm; 2020 Oct; 588():119792. PubMed ID: 32827675
[TBL] [Abstract][Full Text] [Related]
7. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement.
Estapé Senti M; de Jongh CA; Dijkxhoorn K; Verhoef JJF; Szebeni J; Storm G; Hack CE; Schiffelers RM; Fens MH; Boross P
J Control Release; 2022 Jan; 341():475-486. PubMed ID: 34890719
[TBL] [Abstract][Full Text] [Related]
8. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
Hashiba K; Sato Y; Harashima H
J Control Release; 2017 Sep; 262():239-246. PubMed ID: 28774839
[TBL] [Abstract][Full Text] [Related]
9. Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury.
Waggoner LE; Miyasaki KF; Kwon EJ
Biomater Sci; 2023 Jun; 11(12):4238-4253. PubMed ID: 36987922
[TBL] [Abstract][Full Text] [Related]
10. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles.
Yanez Arteta M; Kjellman T; Bartesaghi S; Wallin S; Wu X; Kvist AJ; Dabkowska A; Székely N; Radulescu A; Bergenholtz J; Lindfors L
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3351-E3360. PubMed ID: 29588418
[TBL] [Abstract][Full Text] [Related]
11. Design of abiotic polymer ligand-decorated lipid nanoparticles for effective neutralization of target toxins in the blood.
Koide H; Yamauchi I; Hoshino Y; Yasuno G; Okamoto T; Akashi S; Saito K; Oku N; Asai T
Biomater Sci; 2021 Aug; 9(16):5588-5598. PubMed ID: 34241600
[TBL] [Abstract][Full Text] [Related]
12. Elucidation of lipid nanoparticle surface structure in mRNA vaccines.
Wang MM; Wappelhorst CN; Jensen EL; Chi YT; Rouse JC; Zou Q
Sci Rep; 2023 Oct; 13(1):16744. PubMed ID: 37798336
[TBL] [Abstract][Full Text] [Related]
13. PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective.
Tenchov R; Sasso JM; Zhou QA
Bioconjug Chem; 2023 Jun; 34(6):941-960. PubMed ID: 37162501
[TBL] [Abstract][Full Text] [Related]
14. Investigating the mechanism of action of DNA-loaded PEGylated lipid nanoparticles.
Digiacomo L; Renzi S; Quagliarini E; Pozzi D; Amenitsch H; Ferri G; Pesce L; De Lorenzi V; Matteoli G; Cardarelli F; Caracciolo G
Nanomedicine; 2023 Sep; 53():102697. PubMed ID: 37507061
[TBL] [Abstract][Full Text] [Related]
15. Fluorinated Lipid Nanoparticles for Enhancing mRNA Delivery Efficiency.
Zhang H; Meng C; Yi X; Han J; Wang J; Liu F; Ling Q; Li H; Gu Z
ACS Nano; 2024 Mar; 18(11):7825-7836. PubMed ID: 38452271
[TBL] [Abstract][Full Text] [Related]
16. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
17. Visible Light Conjugation with Triazolinediones as a Route to Degradable Poly(ethylene glycol)-Lipids for mRNA Lipid Nanoparticle Formulation.
Golba B; Soete M; Zhong Z; Sanders N; Du Prez FE; Houck HA; De Geest BG
Angew Chem Int Ed Engl; 2023 Jun; 62(23):e202301102. PubMed ID: 36896730
[TBL] [Abstract][Full Text] [Related]
18. pH-Dependent Phase Behavior and Stability of Cationic Lipid-mRNA Nanoparticles.
Larson NR; Hu G; Wei Y; Tuesca AD; Forrest ML; Middaugh CR
J Pharm Sci; 2022 Mar; 111(3):690-698. PubMed ID: 34774918
[TBL] [Abstract][Full Text] [Related]
19. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery.
Wang X; Liu S; Sun Y; Yu X; Lee SM; Cheng Q; Wei T; Gong J; Robinson J; Zhang D; Lian X; Basak P; Siegwart DJ
Nat Protoc; 2023 Jan; 18(1):265-291. PubMed ID: 36316378
[TBL] [Abstract][Full Text] [Related]
20. Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery.
Kimura N; Maeki M; Sato Y; Ishida A; Tani H; Harashima H; Tokeshi M
ACS Appl Mater Interfaces; 2020 Jul; 12(30):34011-34020. PubMed ID: 32667806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
